AltruBio Inc. Market Research Report

Background

Company Overview

AltruBio Inc. is a clinical-stage biotechnology company headquartered in San Francisco, California, specializing in the development of first-in-class immune-modulators targeting diseases of the immune system. The company's mission is to develop innovative treatments and prevention strategies for inflammatory and autoimmune diseases, aiming to enhance the understanding of immune system regulation and create better therapies for patients.

Mission and Vision

AltruBio is committed to advancing biologic treatments that selectively target unwanted T-cells, thereby addressing chronic immune activation. The company's vision is to provide safer, more durable treatments that improve the lives of patients suffering from immune-mediated diseases.

Industry Significance

Operating within the biotechnology sector, AltruBio focuses on immunology and inflammation, areas with significant unmet medical needs. The company's innovative approach to immune modulation positions it as a potential leader in developing therapies for chronic inflammatory and autoimmune conditions.

Key Strategic Focus

Core Objectives

AltruBio aims to develop novel immune-modulators that can effectively address chronic immune activation, leading to improved patient outcomes in various inflammatory and autoimmune diseases.

Areas of Specialization

The company specializes in immunology and inflammation, focusing on diseases such as ulcerative colitis, psoriatic arthritis, and acute graft-versus-host disease.

Key Technologies Utilized

AltruBio employs a proprietary immune checkpoint regulator mechanism, utilizing PSGL-1 agonist antibodies to selectively target and downregulate chronically activated T-cells. This approach aims to restore immune balance and mitigate disease progression.

Primary Markets Targeted

The company's primary markets include the United States, Europe, and Asia, focusing on regions with high prevalence of immune-mediated diseases and a demand for innovative therapeutic solutions.

Financials and Funding

Funding History

AltruBio has secured substantial funding to support its research and development efforts. In April 2021, the company completed a $63 million Series A funding round, led by aMoon Fund, with participation from BVF Partners L.P., CAM Capital, and others. In May 2024, AltruBio raised an additional $225 million in an oversubscribed Series B financing, led by BVF Partners LP, with participation from RA Capital Management, Cormorant Asset Management, Soleus Capital, aMoon Fund, and Blackstone Multi-Asset Investing.

Utilization of Capital

The funds raised are allocated towards advancing the clinical development of AltruBio's lead candidate, ALTB-268, a PSGL-1 agonist antibody. Specifically, the capital supports ongoing and planned Phase 2 clinical trials in ulcerative colitis and other immunological disorders.

Pipeline Development

Key Pipeline Candidates

• ALTB-268: A next-generation PSGL-1 agonist antibody designed to enhance immune function by downregulating chronically activated T-cells. It has demonstrated improved potency and is suitable for subcutaneous administration. A Phase 2a trial in ulcerative colitis patients was initiated in late 2023.

• ALTB-168: The first-generation PSGL-1 agonist antibody, which has shown clinical efficacy in Phase 2 trials for psoriasis, psoriatic arthritis, and ulcerative colitis. Development continues with ALTB-268, leveraging insights gained from ALTB-168.

Stages of Clinical Trials

• ALTB-268: Currently in Phase 2a clinical trials for ulcerative colitis, with plans to initiate a global Phase 2b randomized, placebo-controlled trial in 2026.

• ALTB-168: Completed Phase 2 trials for psoriasis, psoriatic arthritis, and ulcerative colitis, demonstrating signs of clinical efficacy. Development continues with ALTB-268.

Target Conditions

The primary conditions targeted include ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft-versus-host disease.

Anticipated Milestones

• ALTB-268: Expected readout of the Phase 2a trial in ulcerative colitis in the first half of 2025, with a global Phase 2b trial anticipated to begin in the second half of 2026.

Technological Platform and Innovation

Proprietary Technologies

AltruBio's proprietary technology centers on the PSGL-1 agonist antibody platform, which modulates immune responses by targeting PSGL-1 to downregulate chronically activated T-cells. This approach aims to restore immune balance and mitigate disease progression.

Significant Scientific Methods

The company employs advanced immunological assays and biomarker analyses to evaluate the efficacy and safety of its therapeutic candidates. Additionally, AltruBio utilizes machine learning algorithms to analyze clinical trial data, enhancing decision-making processes in drug development.

Leadership Team

Executive Profiles

• Judy Chou, Ph.D.: President and Chief Executive Officer. Dr. Chou has extensive experience in the biotechnology industry, having previously served as the Global Head of Biotech at Bayer and in leadership roles at Pfizer and Medivation.

• Gene Lee, Ph.D.: Chief Technical Officer. Dr. Lee brings expertise in drug development and technical operations, contributing to AltruBio's R&D initiatives.

• Shih-Yao Lin, M.D., Ph.D.: Vice President of Research. Dr. Lin leads the company's research efforts, focusing on immunology and inflammation.

• Leewen Lin, Ph.D., LL.M.: Vice President of Legal Affairs. Dr. Lin oversees legal and regulatory matters, ensuring compliance and strategic positioning.

• Simona Reed, Ph.D.: Vice President of Clinical Program Management. Dr. Reed manages clinical development programs, coordinating trials and regulatory submissions.

• Adrian Serone, Ph.D.: Vice President of Corporate Program Lead. Dr. Serone leads corporate strategy and program management, aligning business objectives with scientific goals.

• Edwin Powers: Vice President of Business Strategy and Development. Mr. Powers drives business development initiatives, partnerships, and strategic collaborations.

Board of Directors

• Stephen G. Juelsgaard, D.V.M., J.D.: Chairperson of the Board. Mr. Juelsgaard has a background in law and veterinary medicine, with experience in corporate governance and strategic oversight.

• Sean P. Bohen, M.D., Ph.D.: Board Member. Dr. Bohen has a background in medicine and pharmaceutical development, contributing to AltruBio's strategic direction.

• Tomer Berkovitz, Ph.D.: Board Member. Dr. Berkovitz brings expertise in biotechnology and business development to the board.

• John Doyle: Board Member. Mr. Doyle has experience in finance and corporate strategy, supporting AltruBio's financial and operational goals.

• Corsee Sanders, Ph.D.: Board Member. Dr. Sanders offers scientific and clinical insights, enhancing the board's expertise in immunology.

• Patrick Y. Yang, Ph.D.: Board Member. Dr. Yang has a background in biotechnology and drug development, contributing to AltruBio's strategic initiatives.

• Vijay K. Kuchroo, D.V.M., Ph.D.: Chair of the Scientific Advisory Board. Dr. Kuchroo is a professor at Harvard Medical School and a senior scientist at Brigham and Women's Hospital, specializing in immunology.

• Samuel L. Wasserstrom: Board Member. Mr. Wasserstrom has experience in neurology and clinical research, supporting AltruBio's scientific endeavors.

• Fu-Tong Liu, M.D., Ph.D.: Board Member. Dr. Liu is a professor of clinical dermatology at the University of Southern California, contributing expertise in dermatology and immunology.

• Bernard Malissen, Ph.D.: Board Member. Dr. Malissen is the founder and